Acquisition - Schedule of Total Purchase consideration (Details) - Kezar Life Sciences, Inc. $ in Thousands |
May 11, 2026
USD ($)
|
|---|---|
| Asset Acquisition [Line Items] | |
| Cash consideration paid at closing | $ 51,599 |
| CVR consideration payable | 3,700 |
| Transaction costs | 189 |
| Consideration transferred | $ 55,488 |
| X | ||||||||||
- Definition Asset Acquisition, Contingent Value Right, Consideration Payable No definition available.
|
| X | ||||||||||
- Definition Payments For Asset Acquisitions No definition available.
|
| X | ||||||||||
- Definition Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of transaction cost incurred as part of consideration transferred in asset acquisition. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|